CytomX Therapeutics, Inc. announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody TCB molecule to progress in the collaboration and will trigger a $5 million milestone payment to CytomX. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones.

CytomX retains a cost share and co-commercialization option on a select number of targets.